Replimune Group, Inc. (REPL) stock
REPLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q/A on Nov 6, 2026Score 1/30
$21.78−1.50 (-6.44%)
Close on Nov 11, 2026Market cap $2.06BP/E –Yield –
Replimune EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Replimune's EPS for the twelve months ending Sep 30, 2026 was -$2.80. For fiscal 2026 it was -$3.38. The highest annual figure on record is -$1.33 in fiscal 2019.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | -$3.38 | – |
| FY2025 | Mar 31, 2025 | -$3.07 | – |
| FY2024 | Mar 31, 2024 | -$3.24 | – |
| FY2023 | Mar 31, 2023 | -$2.99 | – |
| FY2022 | Mar 31, 2022 | -$2.26 | – |
| FY2021 | Mar 31, 2021 | -$1.75 | – |
| FY2020 | Mar 31, 2020 | -$1.54 | – |
| FY2019 | Mar 31, 2019 | -$1.33 | – |
| FY2018 | Mar 31, 2018 | -$3.96 | – |
| FY2017 | Mar 31, 2017 | -$1.55 | – |
Quarterly eps
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2027CQ3 2026 | Sep 30, 2026 | -$0.54 | – |
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | -$0.72 | – |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | -$0.77 | – |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | -$0.77 | – |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | -$0.90 | – |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | -$0.95 | – |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | -$0.82 | – |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | -$0.79 | – |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | -$0.68 | – |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | -$0.78 | – |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | -$0.83 | – |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | -$0.77 | – |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | -$0.90 | – |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | -$0.75 | – |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | -$0.75 | – |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | -$0.69 | – |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | -$0.79 | – |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | -$0.78 | – |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | -$0.60 | – |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | -$0.57 | – |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | -$0.56 | – |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | -$0.53 | – |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | -$0.42 | – |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | -$0.44 | – |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | -$0.46 | – |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | -$0.44 | – |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | -$0.41 | – |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | -$0.46 | – |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | -$0.35 | – |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | -$0.30 | – |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | -$0.29 | – |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | -$0.24 | – |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | -$0.26 | – |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | -$2.02 | – |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | -$1.43 | – |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | -$0.87 | – |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | -$0.94 | – |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | -$0.71 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?